Is SVRA or FATE more profitable?

Savara has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Fate Therapeutics -1,941.09% -65.08% -41.73%

Does the media refer more to SVRA or FATE?

In the previous week, Fate Therapeutics had 4 more articles in the media than Savara. MarketBeat recorded 5 mentions for Fate Therapeutics and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat Fate Therapeutics' score of 0.66 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRVS or FATE?

In the previous week, Fate Therapeutics had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Fate Therapeutics and 2 mentions for Corvus Pharmaceuticals. Fate Therapeutics' average media sentiment score of 0.66 beat Corvus Pharmaceuticals' score of -0.07 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FATE or JANX?

In the previous week, Janux Therapeutics had 3 more articles in the media than Fate Therapeutics. MarketBeat recorded 8 mentions for Janux Therapeutics and 5 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.66 beat Janux Therapeutics' score of -0.03 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts recommend CVAC or FATE?

Fate Therapeutics has a consensus price target of $5.90, indicating a potential upside of 133.20%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has preferable valuation & earnings, CVAC or FATE?

CureVac has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Fate Therapeutics $6.65M 45.59 -$136.32M -$1.05 N/A

Fate Therapeutics (FATE) Competitors

$2.53 +0.01 (+0.40%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.59 +0.06 (+2.21%)

As of 09/18/2026 07:30 PM Eastern

Compare

FATE vs. SVRA, CRVS, MLTX, JANX, and CVAC

Should you buy Fate Therapeutics stock or one of its competitors? Fate Therapeutics's main competitors and comparable companies include Savara (SVRA), Corvus Pharmaceuticals (CRVS), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), and CureVac (CVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fate Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Fate Therapeutics had 4 more articles in the media than Savara. MarketBeat recorded 5 mentions for Fate Therapeutics and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat Fate Therapeutics' score of 0.66 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

Savara presently has a consensus target price of $10.00, suggesting a potential upside of 86.22%. Fate Therapeutics has a consensus target price of $5.90, suggesting a potential upside of 133.20%. Given Fate Therapeutics' higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Savara has higher earnings, but lower revenue than Fate Therapeutics. Savara is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Fate Therapeutics	$6.65M	45.59	-$136.32M	-$1.05	N/A

Savara has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

87.9% of Savara shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Savara and Fate Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market.

In the previous week, Fate Therapeutics had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Fate Therapeutics and 2 mentions for Corvus Pharmaceuticals. Fate Therapeutics' average media sentiment score of 0.66 beat Corvus Pharmaceuticals' score of -0.07 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 165.39%. Fate Therapeutics has a consensus price target of $5.90, indicating a potential upside of 133.20%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Corvus Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Corvus Pharmaceuticals' return on equity of -36.15% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Fate Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Fate Therapeutics	$6.65M	45.59	-$136.32M	-$1.05	N/A

Summary

Corvus Pharmaceuticals beats Fate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to MoonLake Immunotherapeutics?

Fate Therapeutics (NASDAQ:FATE) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Fate Therapeutics has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Fate Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	45.59	-$136.32M	-$1.05	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, Fate Therapeutics had 2 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 5 mentions for Fate Therapeutics and 3 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Fate Therapeutics' score of 0.66 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Fate Therapeutics presently has a consensus price target of $5.90, indicating a potential upside of 133.20%. MoonLake Immunotherapeutics has a consensus price target of $24.57, indicating a potential upside of 98.32%. Given Fate Therapeutics' higher possible upside, equities research analysts clearly believe Fate Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Fate Therapeutics beats MoonLake Immunotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Fate Therapeutics compare to Janux Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Janux Therapeutics has higher revenue and earnings than Fate Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	45.59	-$136.32M	-$1.05	N/A
Janux Therapeutics	$10M	101.43	-$113.62M	-$1.64	N/A

Fate Therapeutics has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Janux Therapeutics had 3 more articles in the media than Fate Therapeutics. MarketBeat recorded 8 mentions for Janux Therapeutics and 5 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.66 beat Janux Therapeutics' score of -0.03 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Fate Therapeutics currently has a consensus target price of $5.90, indicating a potential upside of 133.20%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 119.78%. Given Fate Therapeutics' higher probable upside, research analysts plainly believe Fate Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Janux Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Janux Therapeutics' return on equity of -11.89% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
Janux Therapeutics	N/A	-11.89%	-11.13%

Summary

Janux Therapeutics beats Fate Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Fate Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Fate Therapeutics' net margin of -1,941.09%. CureVac's return on equity of -23.03% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

CureVac has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Fate Therapeutics	$6.65M	45.59	-$136.32M	-$1.05	N/A

Fate Therapeutics has a consensus price target of $5.90, indicating a potential upside of 133.20%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

17.3% of CureVac shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Fate Therapeutics had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Fate Therapeutics and 0 mentions for CureVac. Fate Therapeutics' average media sentiment score of 0.66 beat CureVac's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Fate Therapeutics	Positive

Summary

Fate Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FATE vs. The Competition

Export

Metric	Fate Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$303.15M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-2.41	14.23	275.49	25.40
Price / Sales	45.59	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.41	15.45	10.46	6.33
Net Income	-$136.32M	-$22.86M	$3.49B	$358.33M
7 Day Performance	9.52%	-1.21%	0.59%	1.12%
1 Month Performance	3.27%	-3.29%	-1.74%	-2.39%
1 Year Performance	162.91%	37.74%	18.13%	5.35%

Fate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FATE Fate Therapeutics	2.581 of 5 stars	$2.53 +0.4%	$5.90 +133.2%	+162.9%	$303.15M	$6.65M	N/A	161	High Trading Volume
SVRA Savara	2.066 of 5 stars	$5.34 +0.8%	$10.00 +87.3%	+52.1%	$1.09B	N/A	N/A	70	Positive News
CRVS Corvus Pharmaceuticals	2.0645 of 5 stars	$13.11 +1.5%	$33.33 +154.3%	+114.0%	$1.09B	N/A	N/A	37	Analyst Forecast
MLTX MoonLake Immunotherapeutics	2.4005 of 5 stars	$12.68 +1.4%	$24.57 +93.8%	-77.0%	$1.06B	N/A	N/A	130	News Coverage Positive News Analyst Forecast
JANX Janux Therapeutics	2.8158 of 5 stars	$17.31 +1.2%	$36.46 +110.6%	-29.3%	$1.05B	$10M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Competitors

FATE vs. SVRA, CRVS, MLTX, JANX, and CVAC

How does Fate Therapeutics compare to Savara?

Summary

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Fate Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Fate Therapeutics compare to Janux Therapeutics?

Summary

How does Fate Therapeutics compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fate Therapeutics (FATE) Competitors

FATE vs. SVRA, CRVS, MLTX, JANX, and CVAC

How does Fate Therapeutics compare to Savara?

Does the media refer more to SVRA or FATE?

Which has more volatility & risk, SVRA or FATE?

Do analysts prefer SVRA or FATE?

Which has better earnings & valuation, SVRA or FATE?

Is SVRA or FATE more profitable?

Do institutionals and insiders hold more shares of SVRA or FATE?

Summary

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Which has more volatility and risk, CRVS or FATE?

Does the media favor CRVS or FATE?

Do analysts prefer CRVS or FATE?

Is CRVS or FATE more profitable?

Do institutionals & insiders have more ownership in CRVS or FATE?

Which has stronger earnings & valuation, CRVS or FATE?

Summary

How does Fate Therapeutics compare to MoonLake Immunotherapeutics?

Which has more risk and volatility, FATE or MLTX?

Which has stronger valuation and earnings, FATE or MLTX?

Does the media favor FATE or MLTX?

Do institutionals and insiders have more ownership in FATE or MLTX?

Is FATE or MLTX more profitable?

Do analysts recommend FATE or MLTX?

Summary

How does Fate Therapeutics compare to Janux Therapeutics?

Which has better earnings & valuation, FATE or JANX?

Which has more volatility and risk, FATE or JANX?

Do insiders and institutionals have more ownership in FATE or JANX?

Does the media favor FATE or JANX?

Do analysts recommend FATE or JANX?

Is FATE or JANX more profitable?

Summary

How does Fate Therapeutics compare to CureVac?

Which has more volatility & risk, CVAC or FATE?

Is CVAC or FATE more profitable?

Which has preferable valuation & earnings, CVAC or FATE?

Do analysts recommend CVAC or FATE?

Do insiders & institutionals have more ownership in CVAC or FATE?

Does the media favor CVAC or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools